bn82002

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BN82002: inhibitor of CDC25 phosphatases; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9798923
CHEMBL ID	1553873
SCHEMBL ID	1917644
MeSH ID	M0467931

Synonyms (25)

Synonym
HSCI1_000079
NCGC00165741-01
bn-82002
CHEMBL1553873
396073-89-5
unii-237srb7uqx
237srb7uqx ,
phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-
SCHEMBL1917644
4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]amino}methyl)phenol
AS-58681
4-(dimethylamino)-2-methoxy-6-({methyl[2-(4-nitrophenyl)ethyl]-amino}methyl)phenol
GOKYHQGRIIXMNE-UHFFFAOYSA-N
EX-A2918
BCP29552
bn82002 pound>>bn-82002 pound>>cdc25 phosphatase inhibitor i, bn82002
bn82002
4-(dimethylamino)-2-methoxy-6-[[methyl-[2-(4-nitrophenyl)ethyl]amino]methyl]phenol
CS-0063820
HY-112776
bn82002 hydrochloride salt
cdc25 phosphatase inhibitor i
Q27253727
D93454
AKOS037515620

Research Excerpts

Overview

BN82002 is a original CDC25 inhibitor that is active both in cell and animal models.

Excerpt	Reference	Relevance
"BN82002 is a original CDC25 inhibitor that is active both in cell and animal models."	( A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Alby, F; Baldin, V; Brezak, MC; Cazales, M; Ducommun, B; Galcera, MO; Harnett, J; Kasprzyk, PG; Lanco, C; Lavergne, O; Mondésert, O; Prevost, GP; Quaranta, M; Thurieau, C, 2004)	1.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	1.7221	0.0032	45.4673	12,589.2998	AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	2.2387	0.0040	23.8416	100.0000	AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	7.9245	0.1409	11.1940	39.8107	AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	53.3729	0.1259	19.1169	125.8920	AID2549; AID2708; AID504841
endonuclease IV	Escherichia coli	Potency	0.6310	0.7079	12.4324	31.6228	AID2565
phosphopantetheinyl transferase	Bacillus subtilis	Potency	11.2202	0.1413	37.9142	100.0000	AID1490
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	14.1254	0.5406	17.6392	96.1227	AID2528
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	2.5119	0.3548	28.0659	89.1251	AID504847
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	25.1189	0.0100	39.5371	1,122.0200	AID1469
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	35.4813	0.0079	8.2332	1,122.0200	AID2551
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	2.9935	0.0316	22.3146	100.0000	AID588579
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	39.8107	0.2512	15.8432	39.8107	AID504327
Glutamate receptor 1	Rattus norvegicus (Norway rat)	Potency	0.2818	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.2818	0.0015	51.7393	15,848.9004	AID2572
Glutamate receptor 3	Rattus norvegicus (Norway rat)	Potency	0.2818	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 4	Rattus norvegicus (Norway rat)	Potency	0.2818	0.0141	8.6024	39.8107	AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Process	via Protein(s)	Taxonomy
plasma membrane	Glutamate receptor 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay ID	Title	Year	Journal	Article
AID644236	Inhibition of recombinant human GST-tagged cdc25A phosphatase activity using 3-O-methyl fluorescein phosphate at 100 uM	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells.
AID644235	Inhibition of recombinant human GST-tagged cdc25C phosphatase activity using 3-O-methyl fluorescein phosphate at 100 uM	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Coumarin polysulfides inhibit cell growth and induce apoptosis in HCT116 colon cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	17.96 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.72 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (17.96)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
thiazoles [no description available]	2.05	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
diallyl disulfide diallyl disulfide: major constituent of garlic oil. diallyl disulfide : An organic disulfide where the organic group specified is allyl. It has been isolated from garlic and other species of the genus Allium.	2.07	1	organic disulfide	antifungal agent; antineoplastic agent; plant metabolite
diallyl tetrasulfide [no description available]	2.07	1	organosulfur compound
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.15	1
2,3-bis(2-hydroxyethylsulfanyl)-(1,4)naphthoquinone 2,3-bis(2-hydroxyethylsulfanyl)-(1,4)naphthoquinone: CDC25A & B inhibitor	2.15	1

Condition	Relationship Strength	Studies
Blood Poisoning [description not available]	2.41	1
Innate Inflammatory Response [description not available]	2.41	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.41	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	2.41	1
Acute Myelogenous Leukemia [description not available]	2.15	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.15	1
Benign Neoplasms, Brain [description not available]	2.05	1
Glial Cell Tumors [description not available]	2.05	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.05	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.05	1
Cancer of Pancreas [description not available]	2.02	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.02	1

chemdatabank.com